These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1273335)

  • 21. [Effects and side effects of levodopa in parkinsonism - results of a collaborative study. (2) The relationship between the age of the onset and therapeutic effects].
    Yokochi M
    Rinsho Shinkeigaku; 1976 Dec; 16(12):871-3. PubMed ID: 1035528
    [No Abstract]   [Full Text] [Related]  

  • 22. Hereditary spastic paraplegia associated with dopa-responsive parkinsonism.
    Micheli F; Cersósimo MG; Zúñiga Ramírez C
    Mov Disord; 2006 May; 21(5):716-7. PubMed ID: 16463348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
    Peppe A; Dambrosia JM; Chase TN
    Adv Neurol; 1993; 60():698-702. PubMed ID: 8420213
    [No Abstract]   [Full Text] [Related]  

  • 24. [Long-term treatment of middle-aged and old patients with paralysis agitans and parkinsonism with levodopa].
    Bogolepov NK; Gorbunov FE
    Vrach Delo; 1975 Aug; (8):126-30. PubMed ID: 1221589
    [No Abstract]   [Full Text] [Related]  

  • 25. [Levodopa as a single treatment of Parkinsonism. Long-term control of 24 cases with discrimination analysis].
    Borromei A; Manzini A
    Minerva Med; 1974 Nov; 65(79):4160-70. PubMed ID: 4610450
    [No Abstract]   [Full Text] [Related]  

  • 26. The sixth year after L-dopa: quality of life and insights derived.
    Boshes B; Arbit J; Dolkart M; Blonsky ER; Kovach JW
    Trans Am Neurol Assoc; 1975; 100():166-8. PubMed ID: 1226599
    [No Abstract]   [Full Text] [Related]  

  • 27. Report on 45-month treatment of parkinsonism with L-dopa, alone and in association with a decarboxilase inhibitor (Ro 4-4602).
    Chouza C; Romero S; Gomensoro JB
    Acta Neurol Latinoam; 1974; 20(1-4):116-38. PubMed ID: 4619960
    [No Abstract]   [Full Text] [Related]  

  • 28. [Mortality in Parkinson's disease and its modification by levodopa (author's transl)].
    Schneider E; Fischer PA; Jacobi P; Kolb R
    Fortschr Neurol Psychiatr; 1981 May; 49(5):187-92. PubMed ID: 7239405
    [No Abstract]   [Full Text] [Related]  

  • 29. [Clinical and psychometric observations on the use of S-adenosylmethionine in parkinsonism during chronic L-dopa treatment].
    Megna G; Pennetta R; Andreula C
    Acta Neurol (Napoli); 1977; 32(2):204-17. PubMed ID: 930659
    [No Abstract]   [Full Text] [Related]  

  • 30. Parkinson's disease: progression and mortality in the L-DOPA era.
    Di Rocco A; Molinari SP; Kollmeier B; Yahr MD
    Adv Neurol; 1996; 69():3-11. PubMed ID: 8615142
    [No Abstract]   [Full Text] [Related]  

  • 31. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism.
    Schwarz J; Tatsch K; Gasser T; Arnold G; Pogarell O; Künig G; Oertel WH
    Mov Disord; 1998 Jan; 13(1):16-9. PubMed ID: 9452320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levodopa in parkinsonism.
    Slome R
    S Afr Med J; 1977 Mar; 51(11):338-40. PubMed ID: 860164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic linkage studies in autosomal dominantly inherited L-DOPA responsive parkinsonism. Evaluation of candidate genes.
    Gasser T; Wszolek Z; Supala A; Trofatter J; Ozelius L; Uitti RJ; Pfeiffer RF; Gusella J; Calne D; Breakefield XO
    Adv Neurol; 1996; 69():87-95. PubMed ID: 8615189
    [No Abstract]   [Full Text] [Related]  

  • 34. [Dystonia preceding dopa-responsive parkinsonism--heterogeneous clinical features].
    Miwa H; Mizuno Y
    No To Shinkei; 1996 Feb; 48(2):149-54. PubMed ID: 8865694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Problems in the administration of L-DOPA (author's transl)].
    Ferrari E
    Riv Patol Nerv Ment; 1974 Aug; 95(4):239-50. PubMed ID: 4283417
    [No Abstract]   [Full Text] [Related]  

  • 36. Dopa responsive dystonia and juvenile Parkinson's disease: two subtypes of the same disorder?
    Lamberti P; de Mari M; Iliceto G; Federico F
    Acta Neurol (Napoli); 1992; 14(4-6):451-4. PubMed ID: 1293988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Augmenting procedures during L-dopa therapy for Parkinsonism.
    Bhaskar PA; Bhaskar EA; Jagannathan K
    J Assoc Physicians India; 1975 Jan; 23(1):21-7. PubMed ID: 1194194
    [No Abstract]   [Full Text] [Related]  

  • 38. [Results of L-dopa treatment of parkinsonism].
    Dowzenko A; Buksowicz C; Kuran W
    Neurol Neurochir Pol; 1975; 9(2):153-8. PubMed ID: 1153050
    [No Abstract]   [Full Text] [Related]  

  • 39. [Unusual symptoms in Parkinsonism: positive effects of L-dopa].
    Morel-Maroger A; Therme F
    Therapie; 1978; 33(1):129-30. PubMed ID: 663891
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effect of L-dopa on EEG tracings in patients with parkinsonism].
    Rudkowska A; Misztal S
    Pol Tyg Lek; 1975 Apr; 30(14):593-5. PubMed ID: 1129202
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.